Thursday, July 19, 2007

Donor selection for hematopoietic cell transplantation

INTRODUCTION — The selection of a donor for a hematopoietic cell transplant procedure is a critical element which contributes to the overall success of the transplant. There are several possible sources for these cells:
An identical twin (syngeneic)
A sibling or unrelated donor (allogeneic)
The patient himself or herself (autologous)
Umbilical cord blood as a source of hematopoietic stem cells.
The decision as to which donor source to utilize depends to a large degree upon the clinical situation and the approaches employed at the individual transplant center. (See "Sources of hematopoietic stem cells"). This topic review will provide an overview of the general issues involved in donor selection for hematopoietic cell transplantation.
GENERAL CONSIDERATIONS — Transplant donors must be in generally good health without other comorbid conditions. The donor must have a performance status that will permit the safe collection of the cells, either by bone marrow (BM) or peripheral blood progenitor cell (PBPC) collection [1]. (See "Sources of hematopoietic stem cells"). Thus, the donor must be able to tolerate anesthesia (either general or regional) and have adequate cardiac, pulmonary, hepatic and renal function. Pediatric donors are only utilized for autologous collection or donation to siblings. Donors with ongoing malignancies or a history of a malignant condition other than minor skin cancers (eg, basal cell carcinomas) are generally excluded from further consideration.
Viral serologic studies are performed on all donors, who must be negative for both anti-HIV antibodies and HIV RNA. (See "Serologic tests for the diagnosis of HIV infection"). Serologic tests for hepatitis B and C are also required at most transplant centers. Donors with active viral hepatitis are usually excluded although exceptions are occasionally made with sibling donors, depending upon the clinical urgency [2]. In certain circumstances, antiviral therapy may be considered if time permits for an adequate course [3].
The following additional studies are routinely performed on hematopoietic cell donors:
History and physical examination, including a careful history of past bleeding events and allergies
Past surgical and obstetrical history
Complete blood count with platelet count
Serum creatinine and electrolytes and liver function studies
Serologic studies for cytomegalovirus (CMV) and herpes viruses
ABO blood typing
Chest x-ray
Electrocardiogram
Effect of donor age and other characteristics — The National Marrow Donor Program has completed a retrospective analysis of 6,978 unrelated bone marrow transplants performed from 1987 to 1999 in order to study the effects of various donor characteristics (eg, age, sex, CMV serologic status, ABO compatibility, race, and parity) on recipient outcome [4]. Mobilized peripheral blood transplants were excluded from this analysis. The following major findings were reported:
Age was the only donor trait significantly associated with overall and disease-free survival. Five-year overall survival rates were 33, 29, and 25 percent for donors aged 18 to 30, 31 to 45, and >45 years, respectively. A similar effect was observed among HLA-mismatched cases.
The cumulative incidence of grade III or IV acute graft versus host disease (GVHD) were 30, 34, and 34 percent for donors aged 18 to 30, 31 to 45, and >45 years, respectively (p = 0.005). The corresponding incidences of chronic GVHD at two years were 44, 48, and 49 percent, respectively (p = 0.02).
Recipients with female donors who had undergone multiple pregnancies had a higher rate of chronic GVHD (54 percent) than recipients with male donors (44 percent, p<0.0001).
Other studies have found that younger donors are associated with lower incidences of secondary graft failure [5], B-cell lymphoproliferative disorders [6], and obstructive lung disease [7] following allogeneic transplantation.
IDENTICAL TWIN DONORS — Rarely, patients who are candidates for hematopoietic cell transplantation have an identical twin who can serve as the donor. These patients do not require posttransplant immunosuppression and do not develop graft-versus-host disease (GVHD). However, they are at a higher risk of relapse of the underlying malignant disease than similar patients transplanted with HLA-matched but nonidentical sibling donors [8]. This is especially true for patients transplanted for acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML), less so for patients with acute lymphoblastic leukemia (ALL) [9], and has not been demonstrated in patients transplanted for non-Hodgkin's lymphoma [10].
These relationships were illustrated in a review from 163 transplant centers which compared the results of 103 identical twin (syngeneic) and 1030 HLA-identical sibling (allogeneic) transplants for leukemia [9]. The three-year probability of relapse of leukemia was substantially higher in the syngeneic than allogeneic transplants in AML (52 versus 16 percent) and CML (40 versus 7 percent); the GVL effect was less apparent and not statistically significant in ALL (36 versus 26 percent).
The reason for this apparent disparity is uncertain but is presumably related to the ability of the donor lymphocytes to recognize the recipient tumor cells, ie, a graft-versus-leukemia (GVL) reaction [11]. Interestingly, survival was similar with the two types of transplants because the increased incidence of leukemia relapse with identical twin transplants was counterbalanced by less treatment-related mortality.
Molecular scrutiny of the blood of the healthy twin (and potential transplant donor) is particularly relevant if the malignant clone in the unhealthy twin may have been present in utero, as has been shown for acute leukemia [12,13]. Under such circumstances, identical twins with a shared placental circulation may be harboring the identical malignant clone, with one twin developing clinically evident leukemia in advance of the other.
MATCHED RELATED DONORS — Related donors are generally siblings since they have the opportunity to inherit the same human leukocyte antigen (HLA) genes located on chromosome 6. There is a 25 percent chance that a given sibling will be HLA-matched at the A, B, and DR loci which are the principal loci evaluated using serologic methods. (See "HLA: A roadmap"). In matched siblings, serologic typing is adequate, since a match at these loci makes it highly likely that the same genes were inherited from the parents.
HLA-matched sibling donors are generally the preferred donor source for an allogeneic transplant. It is unlikely that matched related donors will be anything other than siblings unless the parents happen to have very common haplotypes or there has been intermarrying among families, such that first cousins might be fully HLA-matched.
MISMATCHED RELATED DONORS — In most centers, a complete match at the HLA-A, -B and -DR loci is required for that individual to be used as a transplant donor. In some cases, siblings are mismatched at a single HLA locus. Transplants from single antigen mismatched siblings are associated with a higher risk of GVHD, although overall survival may not be different from that observed with fully matched siblings [14,15]. Thus, the use of one antigen mismatched siblings is considered in some centers, depending upon the clinical situation (eg, high- versus standard-risk patient, amount of time available for a matched unrelated donor search) [15].
Haploidentical donors — Other transplant centers are exploring the use of donors who are only haploidentical and therefore mismatched at three loci [16]. Although encouraging data have been obtained, this approach is only being explored at centers with expertise in this area [17-19]. In one series of 72 such patients, engraftment at 30 days occurred in 88 percent, grade II to IV acute GVHD in 16 percent, and severe chronic GVHD in 8 percent of evaluable patients [18]. Disease status at the time of transplant was the only factor significantly predictive of outcome. The authors concluded that, in patients who will be treated with an allogeneic transplant, progression of the underlying disease can be avoided by using a haploidentical donor.
Another study evaluated the efficacy of haploidentical transplantation with T-cell depleted stem cells in 43 patients with high-risk acute leukemia [20]. Remarkably, full engraftment was achieved in all patients and none of the evaluable patients developed acute or chronic GVHD. Relapse of the underlying disease occurred mainly in patients with acute lymphoblastic leukemia, especially those who were transplanted with advanced disease. Infection was a significant problem which was thought to be due to the slow recovery of T cell immunity. Attempts are ongoing to avoid this problem through adoptive immunotherapy, by adding allodepleted donor T-cells [21].
A novel approach to inducing graft-versus-leukemia (GVL) activity has been identified, namely GVL mediated by donor-derived natural killer (NK) cells. In haploidentical transplants, donor and recipients differ at multiple HLA class I loci, and NK cell-mediated cytotoxicity is to a large extent governed by appropriate MHC class I expression. Thus, NK cells from a haploidentical donor could recognize the recipient as foreign and be alloreactive. In one study, presence of alloreactive NK cells was demonstrated only in those clinical settings predicted by HLA typing [22]. (See "Biology of the graft-versus-tumor effect following hematopoietic cell transplantation", section on Natural killer cells).
In both clinical transplantation studies and mouse modeling, alloreactive NK cells can protect recipients from myeloid (but not lymphoid) leukemia, graft rejection, and GVHD, possibly through destruction of recipient dendritic cells [23]. These observations raise the possibility of selecting donors for NK cell alloreactivity, since, in the haploidentical setting, most patients have a number of possible donors (see below).
A lower risk of developing GVHD with haploidentical donors may result from the ex vivo treatment of donor bone marrow cells with irradiated recipient cells and CTLA-4-Ig (abatacept), an agent which can help render donor T cells anergic to host cells because of the blockade of costimulatory signals. (See "MHC structure and function"). In one study of 12 patients with amegakaryocytic thrombocytopenia, or persistent lymphoma or leukemia, marrow cells from haploidentical donors were incubated for 36 hours with irradiated recipient peripheral mononuclear cells and abatacept [24]. After myeloablation and immunotherapy, treated donor cells were infused into the recipient [24]. Although four patients had GVHD (one with chronic and three with acute disease confined to the gastrointestinal tract), no deaths occurred secondary to GVHD and five patients were in remission 5 to 29 months after HCT.
Maternal versus paternal antigens — Mismatching of maternal, rather than paternal, antigens seems to be better tolerated in haploidentical transplants, presumably due to exposure to maternal HLA antigens during the prenatal and perinatal period [25]. There is evidence that males and nulliparous females are preferred over parous female donors, since the risk of GVHD has been slightly higher in some studies in the latter group [26]. This may be due, in part, to pregnancy- associated alloimmune responses against paternal minor H antigens [27].
This effect was evaluated in a study of 269 subjects receiving one or two antigen-mismatched sibling or parental non-T-cell depleted transplants, using data from the International Bone Marrow Transplant Registry [28]. Results included the following:
Sibling transplants mismatched for paternal antigens had similar rates of transplant-related mortality (TRM) and graft failure, but higher rates of acute GVHD than maternal-mismatched transplants (relative risk (RR): 1.86, 95 percent confidence interval (CI): 1.15 to 3.05).
In the first four months post-transplant, father-to-child transplants involved significantly more chronic GVHD than mother-to-child transplants (RR: 2.44, 95% CI: 1.12-5.34).
When compared with maternal-mismatched sibling transplants, a transplant from either parent was equally likely to be associated with an increase in treatment-related mortality (RR: 2 for each).
Multiple potential donors — One potential advantage of using haploidentical donors is that within a given family there are usually multiple individuals who could serve as potential donors including parents, siblings, and children [29]. As a result, the donor used could be chosen depending upon HLA type, CMV status, blood type, or other features which could have potential clinical implications [30-33]. Another advantage is equal availability of donors for all ethnic and racial groups in contrast to matched unrelated donors (see below).
CMV status — Sibling donors must be in generally good health as discussed above and be serologically negative for viral infection, especially HIV. In the unusual situation in which there is more than one sibling donor, CMV status is usually used to decide which donor to utilize especially if the recipient is CMV seronegative. In this setting, a CMV seronegative donor is preferred since this will greatly reduce the risk of subsequent infection with CMV, assuming that the patient receives CMV seronegative blood products.
ABO and Rh status — ABO and Rh compatibility are not required between the donor and recipient. Hemolysis, delayed erythropoietic engraftment, and pure red cell aplasia (PRCA) may complicate ABO-incompatible transplantation after either marrow or PBSC transplantation, but are not common [34-39]. Similarly, anti-D seldom develops in RhD-mismatched recipients of a myeloablative allogeneic hematopoietic cell transplantation, but may occur following non-myeloablative conditioning [40,41]. Data from two studies suggest that major ABO-incompatibility is not a barrier to successful non-myeloablative transplantation [42,43], although transplant-related morbidity and mortality were higher in a third study [44].
If, however, major mismatches are present, additional manipulation of the hematopoietic cell product, such as depleting the product of red cells or plasma prior to infusion, may [45] or may not [34] be required. It is not clear whether major or minor ABO mismatches are associated with a higher incidence of GVHD and/or reduced overall survival [46-48].
Cases of delayed hemolysis and/or PRCA have been described in patients with pre-existing alloantibodies against Rh or ABO antigens, despite the presence of 100 percent donor chimerism of the circulating lymphocytes [49,50]. This phenomenon, including persistence of other host-derived antibodies post-transplantation, may be due to the presence of long-lived antibody-producing recipient plasma cells surviving the transplantation regimen [50-52]. (See "Acquired pure red cell aplasia").
MATCHED UNRELATED DONORS — In 1986, the National Marrow Donor Program (NMDP) was established as a repository for HLA-typing information so that unrelated donors and recipients could be matched [53]. Many international registries have also formed which allow for the worldwide search for appropriate donors for those in need of a bone marrow transplant procedure [54,55].
At present, there are over four million donors registered in the NMDP data bank, all of whom have undergone HLA-A and -B serologic typing. The number of potential donors is increasing with greater public awareness of the need. A significant percentage have also undergone serologic typing at the C and D region and some have had molecular typing.
It is more difficult to find a donor for patients from certain ethnic and racial backgrounds. As an example, it has been estimated that a matched unrelated graft has been made available for 50 percent of Caucasians compared to less than 10 percent of minorities in need in the United States [18]. This is part due to underrepresentation in the data bank; in addition, African-Americans and Asian-Americans are more polymorphic than Caucasians with respect to HLA and have a relatively large number of haplotypes that are specific to their racial groups, making it more difficult to find donors at any registry size [56,57].
Serologic versus molecular typing — Since the donor and recipient are not related, serologic typing alone does not ensure that those individuals share the same HLA genes. This is evident clinically by the higher risk of GVHD in recipients of unrelated donor grafts [58]. DNA-based techniques have been developed which permit molecular typing, which has demonstrated that only about 55 percent of serologically identical donor and recipient pairs (ie, antigen matched) are highly matched by molecular typing (ie, allele matched) [59-63]. Patients who are truly highly matched appear to have better outcomes:
In one series of 44 unrelated patient-donor pairs who were serologically matched, the 24 patients who were highly matched by molecular techniques had a 21 percent incidence of severe GVHD compared to 47 percent in those who were not highly matched [59]. Other significant advantages in the highly matched patients were a lower transplant-related mortality (21 versus 57 percent) and a higher three year actuarial survival (61 versus 13 percent).
In a second report, molecular DNA typing was performed in 440 recipients transplanted from unrelated donors who were serologically identical with their donors for HL-A, B, and DR antigens [60]. When DNA-based genotyping was performed, only 55 percent were identical at the tested HLA-A, B, and DR alleles and 69 percent were identical at the HLA-C alleles which were not tested serologically. HLA-DP matching was present in less than 50 percent but did not appear to affect the outcome. Multivariate analysis showed that mismatching at the HLA-A allele was an independent risk factor for severe GVHD and death (show figure 1), and that mismatching at the HLA-C allele was an independent risk factor for severe GVHD and for a lower rate of recurrence of leukemia in those transplanted for that disease (show figure 2). The importance of class C mismatching has been noted in another series in which patients who had an HLA-C disparity had a relative risk for graft failure of 4.0 after accounting for the contribution HLA-A and HLA-B mismatches [62].
In a study of 1874 donor-recipient pairs retrospectively typed at both low and high resolution, mismatches at HLA-A, -B, -C, and -DR1 each had similar adverse effects on mortality, while only HLA-A mismatches demonstrated significant effects on GVHD [64]. Adverse effects on outcome were more evident in transplants with low-resolution (ie, antigenic) versus only high-resolution (ie, allelic or molecular) mismatches. Of importance, mismatching at the HLA-DQ or -DP loci did not significantly affect outcome.
The question of which mismatches are tolerated and which result in adverse clinical outcomes continues to be actively investigated. Most transplant centers now require complete serologic and molecular matching at the class II region to use that donor for a given transplant procedure. However, as noted above with siblings, the degree of HLA disparity which is tolerable depends upon many factors, including the clinical situation of the recipient [65].
Use of these various advances has resulted in continued improvement in the outcome of patients transplanted with bone marrow obtained from unrelated donors [66,67]. Reducing the degree of mismatch with sophisticated genotyping has, as noted above, resulted in decreased mortality following unrelated bone marrow transplants [59,60,68]. However, requiring more specific testing will undoubtedly reduce the number of donors available for an individual patient and may increase the amount of time required to locate a match, since the vast majority of patients in the registries have been typed with serologic assays.
Time is an issue even with serologic typing as it may take up to six months to complete a search for a matched unrelated donor. This is largely due to the lack of complete typing data for the entire donor population and the large expense required to perform all of the typing tests on all possible donors. In one study of 240 patients of Dutch origin, for example, an appropriate donor could be identified in approximately 70 percent of cases [69]. The search required six months. Approximately one-third of patients were transplanted, one-third had a potential donor but did not receive the transplant, and one-third did not have a suitable donor.
The long search times make this approach feasible only for those diseases with suitable clinical courses. This includes chronic myelogenous leukemia (CML), myelodysplastic syndromes, and aplastic anemia, and when searches are initiated early in the course of treatment of patients with high-risk leukemias. (See appropriate topic reviews).
Once an appropriate donor is identified through the registry, the donor must be screened as discussed above for general health and suitability. The bone marrow is harvested locally and then transported to the transplant center. It is feasible to collect donor hematopoietic cells virtually anywhere in the world.
Due to the higher risk of GVHD in recipients of matched unrelated donor transplants [57], T-cell depletion techniques have been employed in an attempt to reduce this complication:
One approach is to utilize anti-thymocyte globulin (ATG) [67]. In one study, fifty-five adults with AML, CML, or MDS received matched unrelated transplants with GVHD prophylaxis including ATG, cyclosporine, and methotrexate [70]. The incidence of acute GVHD (grade II-IV) was 15 percent, which appears favorable. Chronic GVHD occurred in 51 percent of the patients; graft failure did not occur. The cumulative incidence of relapse within one year was zero. All 14 patients with CML became bcr-abl negative within 250 days.
A national trial is underway comparing the outcomes of patients who undergo T-cell depletion using the B10T9 monoclonal antibody as compared to those patients who undergo a conventional T-cell replete transplant.
Predictors of engraftment and survival — The results in 5,246 patients who underwent unrelated donor bone marrow transplantation facilitated by the National Marrow Donor Program between August, 1991 and June, 1999 have been reported [5]. The following donor and recipient factors were significantly associated with successful engraftment:
Hematopoietic cells matched at HLA-A, HLA-B, and DRB1
Higher cell dose
Younger recipient
Male recipient
Recipient from a non-African American ethnic group
CMV status — In the above study, recipient seronegativity for CMV was associated with more rapid myeloid and platelet engraftment; other studies have also shown a lower risk of treatment-related mortality and improved survival for CMV seronegative recipients transplanted with seronegative donors [71-73].
However, a CMV seropositive donor may be preferred when the recipient is CMV seropositive. A retrospective EBMT study indicated significantly better event-free survival (30 versus 22 percent), five-year overall survival (35 versus 27 percent), and transplant-related mortality (49 versus 62 percent) when CMV seropositive patients received CMV seropositive, rather than seronegative unrelated donor transplants [74]. This benefit was abrogated by T-cell depletion, suggesting that the effect was mediated through transfer of donor immunity.
Umbilical cord blood donors — Relatively high numbers of hematopoietic stem cells are present in umbilical cord blood collected at the time of delivery. These cells can be processed and cryopreserved in cord blood banks. (See "Sources of hematopoietic stem cells"). Following HLA-matching to a recipient, the cord blood unit can be transported to the transplant center with minimal delay and used.
Due to the relative immaturity of the immune system in cord samples, stem cells from this source allow the crossing of immunologic barriers that would otherwise be prohibitive. As a result, the degree of HLA-disparity which is tolerable is much greater. In one series of 25 children (24 of whom were discordant for one to three HLA antigens), cord blood stem cell transplantation was associated with engraftment in 23 and with acute severe GVHD in only 2 of 21 evaluable cases [75].
A major advantage of the use of cord blood is that the cells are already collected and cryopreserved, which greatly reduces the time required for accessing the donor and completing the transplant procedure [76]. In addition, the degree of mismatching tolerated with cord blood transplantation may make this approach more feasible for members of minorities that are underrepresented in volunteer donor registries. (See "Collection and storage of umbilical cord blood for hematopoietic cell transplantation").
Efficacy — Engraftment occurs after infusion of cord blood products, although it may be delayed in some instances depending upon the number of cells and size of the recipient. One report evaluated 562 recipients who were usually matched for at least five of six of the unrelated placental blood donor's HLA-A, -B, and -DR antigens [77]. The median time to engraftment was 28 days for neutrophils and 90 days for platelets; 81 percent were engrafted for neutrophils by day 42 and 85 percent of platelets by day 180.
Long-term survival has been accomplished, depending upon the source of the cord blood and the nature of the underlying disease [77,78].
In one review of 78 recipients of cord blood from related donors, estimated one year survival was 63 percent; GVHD of at least grade II occurred in 9 percent of HLA-matched recipients and 50 percent of HLA-mismatched recipients [78]. The results were not as good in 65 patients who received cord blood from unrelated donors: estimated one year survival was only 29 percent.
Somewhat better results with unrelated cord blood donors were noted in the above series of 562 patients: severe acute GVHD occurred in 23 percent and chronic GVHD in 25 percent [77].
Limitations — A major limitation is the relatively small volume of the cord blood collections which makes it difficult to use this approach for transplantation in larger adults. The possibility of expanding the cord blood stem cells in vitro is an area of active investigation.
Another potential problem is the possibility of bacterial contamination in cord blood collections which could complicate the transplant procedure. In one careful evaluation of cord blood collection and processing practices, bacterial contamination occurred in 18 percent of collections, a level which could be reduced to below 1 percent with practical experience [79]. Cord blood was associated with a low risk of CMV positivity (0.3 percent of samples). Thus, the likelihood of developing CMV infection following a cord blood transplant is primarily related to the recipient status. Among 500 recipients with known CMV status, the incidence of CMV infection was 23 percent in seropositive recipients and 3 percent in seronegative recipients [77].
Initiating the search — To initiate a preliminary search of the National Marrow Donor Program (NMDP), contact the NMDP Office of Patient Advocacy at the following toll-free telephone number:1-888-999-6743. Alternatively, a preliminary search request form can be submitted through the NMDP website at www.marrow.org [80].
INFORMATION FOR PATIENTS — Educational materials on this topic are available for patients. (See "Patient information: Overview of bone marrow transplantation"). We encourage you to print or e-mail this topic review, or to refer patients to our public web site, www.patients.uptodate.com, which includes this and other topics.
OVERALL APPROACH AND CONCLUSIONS — At present, there are multiple options available in selecting a donor and stem cell source. (See "Sources of hematopoietic stem cells"). As a result, firm recommendations cannot be made. The clinical problem, overall health of the donor and recipient, infectious history, clinical approach of the transplant center, and other factors are important in deciding what type of donor is selected.
Most transplant centers prefer an identical twin donor in those rare instances when one is available and, in other patients, an HLA-matched sibling donor for allogeneic transplantation when one is available [58]. If an HLA-matched sibling donor is not available, then searching the bone marrow registry for unrelated matched donors is the next most suitable option [81]. The roles of cord blood donors and mismatched related donors are areas of ongoing clinical investigation in which results are continuing to improve [82,83]. With all of these approaches, donor safety is of paramount importance and careful screening is imperative to avoid unforeseen complications

No comments: